10X Genomics (TXG) has disclosed a new risk, in the Environmental / Social category.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
10X Genomics is navigating uncertain waters as recent activities among its top brass suggest potential shifts in insider confidence. James L. Wilbur, the former Chief Commercial Officer, abruptly terminated his Rule 10b5-1 trading arrangement, initially set to facilitate the sale of 147,095 shares, well before its December 2024 expiration. Meanwhile, Board member Shehnaaz Suliman and Chief Scientific Officer Benjamin J. Hindson have both initiated new trading arrangements for the sale of company stock, with expiration dates in mid-2024 and 2025, respectively. These insider trading decisions could signal varying expectations for the company’s future performance and may influence investor perception.
Overall, Wall Street has a Moderate Buy consensus rating on TXG stock based on 7 Buys, 1 Sell and 3 Holds.
To learn more about 10X Genomics’ risk factors, click here.